Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.

Raphael O Anyango, Bryan O Nyawanda, Brian O Onyando, Fadima C Haidara, Collins Okello, Ian K Orege, Sidney Ogolla, Billy Ogwel, Alex O Awuor, Samuel Kadivane, Philip Ngere, Carolyne Nasimiyu, Eric Osoro, M Kariuki Njenga, Victor Akelo, Amos Otedo, Shirley Lidechi, John B Ochieng, Nancy A Otieno, Erick M O Muok, Kibet Sergon, Archibald Kwame Worwui, Goitom G Weldegebriel, Isabel Bergeri, Cohuet Sandra, Celine Gurry, J Pekka Nuorti, Patrick Amoth, Rose Jalang'o, Jason M Mwenda, Samba O Sow, Richard Omore
{"title":"Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.","authors":"Raphael O Anyango, Bryan O Nyawanda, Brian O Onyando, Fadima C Haidara, Collins Okello, Ian K Orege, Sidney Ogolla, Billy Ogwel, Alex O Awuor, Samuel Kadivane, Philip Ngere, Carolyne Nasimiyu, Eric Osoro, M Kariuki Njenga, Victor Akelo, Amos Otedo, Shirley Lidechi, John B Ochieng, Nancy A Otieno, Erick M O Muok, Kibet Sergon, Archibald Kwame Worwui, Goitom G Weldegebriel, Isabel Bergeri, Cohuet Sandra, Celine Gurry, J Pekka Nuorti, Patrick Amoth, Rose Jalang'o, Jason M Mwenda, Samba O Sow, Richard Omore","doi":"10.1016/j.vaccine.2025.127234","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Understanding the epidemiology of SARS-CoV-2 infection in settings with limited data, especially given the dynamic nature of the virus and the reported epidemiological heterogeneity across countries, is important. We used data from the COVID-19 Vaccine effectiveness evaluation to determine factors associated with SARS-COV-2 infection among patients (≥ 12 years) with severe respiratory illness (SRI) in Kenya and Mali.</p><p><strong>Methods: </strong>SRI was defined as acute onset (≤ 14 days) of at least two of the following: cough, fever, chills, rigors, myalgia, headache, sore throat, fatigue, congestion or runny nose, loss of taste or smell, or pneumonia diagnosis. We collected demographic and clinical characteristics of the patients, and nasopharyngeal and oropharyngeal specimens for SARS-CoV-2 testing using RT-PCR. We used a mixed effect logistic regression to determine factors associated with SARS-CoV-2 infection adjusting for age and sex while controlling for clustering by site and month of illness onset.</p><p><strong>Results: </strong>Between July 2022 and October 2023, a total of 9941 patients with SRI were enrolled, of whom, 588 (5.9 %) tested positive for SARS-CoV-2. Compared to patients aged 12-24 years, those who were aged >64 years were more likely to have SARS-CoV-2 infection (adjusted Odds Ratio [aOR] = 1.60; 95 % Confidence Interval [95 % CI] 1.07-2.40). Additionally, SRI patients presenting with cough (aOR = 1.37; 95 % Confidence Interval [95 % CI] 1.05-1.80), sore throat (aOR = 1.56; 95 % CI 1.23-1.99), runny nose (aOR = 1.51; 95 % CI 1.18-1.94), and ear pain discharge (aOR = 2.58; 95 % CI 1.43-4.66) were more likely to have SARS-CoV-2 infection compared to those who did not. SRI patients who had HIV were also more likely to have SAR-CoV-2 infection compared to those who did not (aOR =1.32; 95 % CI 1.04-1.67).</p><p><strong>Conclusion: </strong>Older adults and HIV patients were at increased-risk of SARS-CoV-2 infection consistent with WHO guidelines highlighting the need for targeted prevention and management strategies focused on them.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127234"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.vaccine.2025.127234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Understanding the epidemiology of SARS-CoV-2 infection in settings with limited data, especially given the dynamic nature of the virus and the reported epidemiological heterogeneity across countries, is important. We used data from the COVID-19 Vaccine effectiveness evaluation to determine factors associated with SARS-COV-2 infection among patients (≥ 12 years) with severe respiratory illness (SRI) in Kenya and Mali.

Methods: SRI was defined as acute onset (≤ 14 days) of at least two of the following: cough, fever, chills, rigors, myalgia, headache, sore throat, fatigue, congestion or runny nose, loss of taste or smell, or pneumonia diagnosis. We collected demographic and clinical characteristics of the patients, and nasopharyngeal and oropharyngeal specimens for SARS-CoV-2 testing using RT-PCR. We used a mixed effect logistic regression to determine factors associated with SARS-CoV-2 infection adjusting for age and sex while controlling for clustering by site and month of illness onset.

Results: Between July 2022 and October 2023, a total of 9941 patients with SRI were enrolled, of whom, 588 (5.9 %) tested positive for SARS-CoV-2. Compared to patients aged 12-24 years, those who were aged >64 years were more likely to have SARS-CoV-2 infection (adjusted Odds Ratio [aOR] = 1.60; 95 % Confidence Interval [95 % CI] 1.07-2.40). Additionally, SRI patients presenting with cough (aOR = 1.37; 95 % Confidence Interval [95 % CI] 1.05-1.80), sore throat (aOR = 1.56; 95 % CI 1.23-1.99), runny nose (aOR = 1.51; 95 % CI 1.18-1.94), and ear pain discharge (aOR = 2.58; 95 % CI 1.43-4.66) were more likely to have SARS-CoV-2 infection compared to those who did not. SRI patients who had HIV were also more likely to have SAR-CoV-2 infection compared to those who did not (aOR =1.32; 95 % CI 1.04-1.67).

Conclusion: Older adults and HIV patients were at increased-risk of SARS-CoV-2 infection consistent with WHO guidelines highlighting the need for targeted prevention and management strategies focused on them.

与严重呼吸道疾病(SRI)患者实验室确诊的SARS-Cov-2感染相关的因素:2022-2023年肯尼亚和马里COVID-19疫苗有效性评估结果
背景:在数据有限的情况下,了解SARS-CoV-2感染的流行病学非常重要,特别是考虑到该病毒的动态性和各国报告的流行病学异质性。我们使用来自COVID-19疫苗有效性评估的数据来确定肯尼亚和马里严重呼吸道疾病(SRI)患者(≥12岁)中SARS-COV-2感染的相关因素。方法:SRI定义为急性发作(≤14天)至少出现以下两种症状:咳嗽、发热、寒战、僵硬、肌痛、头痛、喉咙痛、疲劳、充血或流鼻涕、味觉或嗅觉丧失,或肺炎诊断。我们收集了患者的人口学和临床特征,并采用RT-PCR方法收集了鼻咽和口咽标本进行SARS-CoV-2检测。我们使用混合效应逻辑回归来确定与SARS-CoV-2感染相关的因素,调整年龄和性别,同时控制按地点和发病月份聚集的因素。结果:在2022年7月至2023年10月期间,共有9941例SRI患者入组,其中588例(5.9%)检测出SARS-CoV-2阳性。与12-24岁的患者相比,bb0 - 64岁的患者更容易感染SARS-CoV-2(校正优势比[aOR] = 1.60;95%置信区间[95% CI] 1.07-2.40)。此外,伴有咳嗽的SRI患者(aOR = 1.37;95%可信区间[95% CI] 1.05-1.80),喉咙痛(aOR = 1.56;95% CI 1.23-1.99),流鼻涕(aOR = 1.51;95% CI 1.18-1.94),耳痛排出(aOR = 2.58;95% CI 1.43-4.66)感染SARS-CoV-2的可能性高于未感染的患者。与未感染艾滋病毒的患者相比,感染艾滋病毒的SRI患者也更容易感染sars - cov -2 (aOR =1.32;95% ci 1.04-1.67)。结论:老年人和艾滋病毒患者感染SARS-CoV-2的风险增加,这与世卫组织的指导方针一致,强调需要针对老年人制定有针对性的预防和管理战略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信